9:
A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling.
Posadas EM, Kwitkowski V, Kotz HL, Espina V, Minasian L, Tchabo N, Premkumar A, Hussain MM, Chang R, Steinberg SM, Kohn EC.
Cancer. 2007 Jul 15;110(2):309-17.
PMID: 17559139 [PubMed - indexed for MEDLINE]
Related Articles
11:
Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
Garg M, Chaurasiya D, Rana R, Jagadish N, Kanojia D, Dudha N, Kamran N, Salhan S, Bhatnagar A, Suri S, Gupta A, Suri A.
Clin Cancer Res. 2007 Mar 1;13(5):1421-8.
PMID: 17332284 [PubMed - indexed for MEDLINE]
Related Articles
17:
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.
Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E.
Cancer Res. 2007 Feb 15;67(4):1670-9.
PMID: 17308108 [PubMed - indexed for MEDLINE]
Related Articles
18:
Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII.
Koizume S, Jin MS, Miyagi E, Hirahara F, Nakamura Y, Piao JH, Asai A, Yoshida A, Tsuchiya E, Ruf W, Miyagi Y.
Cancer Res. 2006 Oct 1;66(19):9453-60.
PMID: 17018600 [PubMed - indexed for MEDLINE]
Related Articles